In a cohort of 142 HD patients, we examined the potential of serum ICAM-1 as a CVD biomarker and evaluated whether confounding factors, including low-grade inflammation and chronic kidney disease-mineral bone disorder (CKD-MBD), limit its diagnostic value. This evidence concerns the gene ICAM1 and abnormal mineralization disorder.